AR071779A1 - Formulaciones de emulsion narcotica para el tratamiento del dolor quirurgico - Google Patents

Formulaciones de emulsion narcotica para el tratamiento del dolor quirurgico

Info

Publication number
AR071779A1
AR071779A1 ARP090101725A ARP090101725A AR071779A1 AR 071779 A1 AR071779 A1 AR 071779A1 AR P090101725 A ARP090101725 A AR P090101725A AR P090101725 A ARP090101725 A AR P090101725A AR 071779 A1 AR071779 A1 AR 071779A1
Authority
AR
Argentina
Prior art keywords
emulsion formulations
surgical pain
narcotic
subject
emulsion
Prior art date
Application number
ARP090101725A
Other languages
English (en)
Original Assignee
Teikoku Pharma Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma Usa Inc filed Critical Teikoku Pharma Usa Inc
Publication of AR071779A1 publication Critical patent/AR071779A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan metodos y composiciones para tratar en un sujeto el dolor posquirurgico. En los metodos se trata en un sujeto el dolor posquirurgico mediante la administracion al sujeto de una cantidad eficaz de una formulacion de emulsion narcotica, por ej., una emulsion de fentanilo. En ciertas formas de realizacion, las formulaciones de emulsion incluyen un agente activo narcotico, aceite, agua y un tensioactivo. Tambien se proporcionan metodos para realizar las formulaciones de emulsion como as¡ tambien kits que incluyen las formulaciones de emulsion.
ARP090101725A 2008-05-15 2009-05-13 Formulaciones de emulsion narcotica para el tratamiento del dolor quirurgico AR071779A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5357108P 2008-05-15 2008-05-15
US12/424,382 US20090286832A1 (en) 2008-05-15 2009-04-15 Narcotic emulsion formulations for treatment of surgical pain

Publications (1)

Publication Number Publication Date
AR071779A1 true AR071779A1 (es) 2010-07-14

Family

ID=41316744

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101725A AR071779A1 (es) 2008-05-15 2009-05-13 Formulaciones de emulsion narcotica para el tratamiento del dolor quirurgico

Country Status (16)

Country Link
US (1) US20090286832A1 (es)
EP (1) EP2276440A4 (es)
JP (2) JP5689053B2 (es)
KR (1) KR101361479B1 (es)
CN (1) CN101938963A (es)
AR (1) AR071779A1 (es)
AU (1) AU2009246713B2 (es)
BR (1) BRPI0907224A2 (es)
CA (1) CA2710546A1 (es)
EA (1) EA201000991A1 (es)
IL (1) IL209145A0 (es)
MX (1) MX2010007698A (es)
NZ (1) NZ586461A (es)
TW (2) TWI413531B (es)
WO (1) WO2009140059A2 (es)
ZA (1) ZA201004392B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286832A1 (en) * 2008-05-15 2009-11-19 Kiichiro Nabeta Narcotic emulsion formulations for treatment of surgical pain
CN102333443A (zh) * 2009-02-26 2012-01-25 帝国制药美国公司 治疗癌症疼痛的麻醉乳液制剂
JP6081240B2 (ja) * 2013-03-13 2017-02-15 テルモ株式会社 レミフェンタニル注射液剤
WO2016038734A1 (ja) 2014-09-12 2016-03-17 テルモ株式会社 レミフェンタニル注射液剤
WO2021252449A1 (en) * 2020-06-08 2021-12-16 Harm Reduction Therapeutics, Inc. Sterilized formulations

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 ４−ビフエニリル酢酸系化合物含有脂肪乳剤
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
ATE183092T1 (de) * 1995-10-28 1999-08-15 Braun Melsungen Ag Lokalanästhetika und/oder zentralanalgetika enthaltende pharmazeutische zusammensetzungen
GB9721746D0 (en) * 1997-10-15 1997-12-10 Panos Therapeutics Limited Compositions
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
US7211596B2 (en) * 2001-05-11 2007-05-01 Mitsubishi Pharma Corporation Stable high-concentration injection containing pyrazolone derivative
DK1509492T3 (da) * 2002-01-25 2011-11-28 Theravance Inc Sedative hypnotiske midler med kort virkningsvarighed til anæstesi og sedation
JP2004043479A (ja) * 2002-07-11 2004-02-12 Taiho Yakuhin Kogyo Kk 経鼻吸収用組成物
BR0315164A (pt) * 2002-10-08 2005-08-23 Rinat Neuroscience Corp Métodos para tratar dor pós-cirúrgica administrando um antagonista de fator de crescimento nervoso e composições contendo o mesmo
UA80447C2 (en) * 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7648982B2 (en) * 2003-02-28 2010-01-19 Ym Biosciences Inc. Opioid delivery system
JP2004275852A (ja) * 2003-03-14 2004-10-07 Mitsubishi Heavy Ind Ltd 排煙脱硝触媒及びその製造方法
WO2005112926A1 (en) * 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
DE102004025357B4 (de) * 2004-05-19 2007-03-29 Beiersdorf Ag Emulsionskonzentrat mit wasserlöslichen und öllöslichen Polymeren und kosmetische Zubereitung enthaltend Emulsionskonzentrat sowie ein Verfahren zu dessen Herstellung und dessen Verwendung
US7871632B2 (en) * 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
US20060189682A1 (en) * 2005-02-02 2006-08-24 Payne Joseph E Water soluble prodrugs of COX-2 inhibitors
DE602006017979D1 (de) * 2005-03-14 2010-12-16 Otsuka Pharma Co Ltd Kit enthaltend einen wirkstoff und eine fettemulsion
EP1928414A2 (en) * 2005-04-22 2008-06-11 Novacardia, Inc. Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
RU2432950C2 (ru) * 2006-01-25 2011-11-10 Инсис Терапьютикс Инк. Подъязычный спрей на основе фентанила
US20090286832A1 (en) * 2008-05-15 2009-11-19 Kiichiro Nabeta Narcotic emulsion formulations for treatment of surgical pain
CN102333443A (zh) * 2009-02-26 2012-01-25 帝国制药美国公司 治疗癌症疼痛的麻醉乳液制剂

Also Published As

Publication number Publication date
KR101361479B1 (ko) 2014-02-12
JP2011520883A (ja) 2011-07-21
WO2009140059A2 (en) 2009-11-19
ZA201004392B (en) 2011-06-29
TWI413531B (zh) 2013-11-01
EA201000991A1 (ru) 2011-06-30
AU2009246713B2 (en) 2012-10-25
AU2009246713A1 (en) 2009-11-19
EP2276440A4 (en) 2011-06-29
CA2710546A1 (en) 2009-11-19
KR20100126270A (ko) 2010-12-01
MX2010007698A (es) 2010-11-22
CN101938963A (zh) 2011-01-05
JP2014205681A (ja) 2014-10-30
BRPI0907224A2 (pt) 2019-02-26
TW201006508A (en) 2010-02-16
TW201406403A (zh) 2014-02-16
IL209145A0 (en) 2011-01-31
WO2009140059A3 (en) 2010-01-07
JP5889364B2 (ja) 2016-03-22
US20090286832A1 (en) 2009-11-19
NZ586461A (en) 2012-07-27
JP5689053B2 (ja) 2015-03-25
EP2276440A2 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
SV2016005320A (es) Formulaciones y mã‰todos de tratamiento con queratina
AR068195A1 (es) Composiciones y metodos para el tratamiento de semillas
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
GT201400043A (es) Imidazopiridazinas sustituidas con amino
UY30210A1 (es) Método para inducir tolerancia viral en plantas
UY28862A1 (es) Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii
BRPI0925036B8 (pt) uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele
UY33598A (es) Imidazopiridazinas sustituidas
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CL2010001260A1 (es) Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis.
ECSP12012037A (es) Composiciones oftálmicas no irritantes de iodopovidona
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
EA201190344A1 (ru) Составы для лечения боли в глубоких тканях
AR071779A1 (es) Formulaciones de emulsion narcotica para el tratamiento del dolor quirurgico
AR056500A1 (es) Metodo para preparar una composicion medica
UY31780A (es) Fenoxibenzamidas sustituidas
CU20170086A7 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
AR075274A1 (es) Agente de tratamiento de semillas y metodo para proteger una planta
PA8797601A1 (es) Agente esterilizante quimico para control de la poblacion de perros machos adultos con reduccion concomitante de rabias por mordeduras en humanos
NI201100201A (es) Metodo y composición para el control de parásitos
AR087790A1 (es) Uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas
UY33790A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.
BR112016029996A2 (pt) utilização cosmética, composição e método cosmético para tratar os odores corporais
CO6761349A2 (es) Proteína antimicrobiana

Legal Events

Date Code Title Description
FA Abandonment or withdrawal